

ASX ANNOUNCEMENT

24 October 2018

RESPIRI

A Breath of Fresh Ideas



NEW BOARD MEMBER APPOINTED

Respiri Limited (ASX:RSH) is pleased to announce the appointment of Dr Tom Duthy as an Independent Non-Executive Director of the Company.

Tom is currently Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory, investor relations and equity research firm. Prior to establishing Nemean, Tom was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX). Sirtex is a global medical device player focused on the sale and development of innovative interventional oncology products and until prior to a takeover, was an S&P/ASX 200 listed Company. In September 2018, Sirtex was sold for A\$1.9 billion to a consortium led by CDH Investments, a China-based alternative asset manager with over US\$20 billion under management. The transaction was the largest in Australian medical device history, and a top ten Med Tech M&A deal globally over the last 12 months. During his time at Sirtex, Tom was instrumental in developing corporate strategies designed to maximise shareholder value.

Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small-cap companies. Tom holds a PhD (with commendation) from the University of Adelaide and an MBA from Deakin University. He is a Member of the Australian Institute of Company Directors (MAICD) and the Australasian Investor Relations Association (AIRA).

Mr Mark Ziirsen, Chairman of Respiri, said “On behalf of the Board, I take great pleasure in announcing Tom’s appointment as a Non-Executive Director of the Company. Tom has substantial experience in the financial markets with a proven track record of delivering shareholder value, which is highly complementary to the Board’s existing mix of skills and competence. As the Company transitions from a developer of innovative wheeze detection and asthma management technologies to product commercialisation activities in 2019, the Board’s collective experience will be essential for executing our plans.”

A handwritten signature in blue ink, appearing to read 'Mark Ziirsen', with a long horizontal line extending to the right.

Mark Ziirsen
Chairman

ABOUT RESPIRI LIMITED

Respiri's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respiri Limited's operations are based in Melbourne, Australia.

FORWARD LOOKING STATEMENTS

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.